Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• FF/UMEC/VI (Trelegy Ellipta) significantly increased trough FEV1 (forced expiratory volume in 1 s) at 24 weeks compared to other triple therapy options, except UMEC + FF/VI, in adults aged ≥40 years with moderate to very severe COPD.
• FF/UMEC/VI showed statistically significant reductions in the annualized rate of combined moderate or severe exacerbations versus BUD/GLY/FOR and UMEC + FF/VI, as well as improvements in SGRQ scores and reductions in rescue medication use over 24 weeks.
• BUD/GLY/FOR and BGF MDI demonstrated comparable efficacy to FF/UMEC/VI in improving lung function, reducing exacerbation rates, and enhancing health-related quality of life at both 24 and 52 weeks.
• The safety profile of FF/UMEC/VI was not detailed in the reviewed studies.
• BUD/GLY/FOR and BGF MDI were found to have a safety and tolerability profile comparable to other ICS/LAMA/LABA fixed-dose and open combination therapies, with no statistically significant differences in safety outcomes for BGF MDI.
• There is no population types or subgroups information available in the reviewed studies.